Latest 10-K annual reports

Alussa Energy Acquisition Corp. II, a blank check company, filed its annual 10-K report for 2025, detailing its initial public offering, financial position, and ongoing search for a business combination in the energy sector.

Calidi Biotherapeutics reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite advancing its RedTail platform and securing recent financings.

Manhattan Bridge Capital reported a decrease in 2025 net income and revenue, while successfully extending key credit facilities and continuing its share repurchase program.

GD Culture Group Limited reported a significant net loss of $186.9 million for fiscal year 2025, primarily due to unrealized losses on Bitcoin holdings, while strategically transitioning its core business to AI-driven interactive reading and narrative entertainment.

Hoth Therapeutics, Inc. reported a significant increase in net loss for 2025, alongside a going concern warning from its auditors, despite progress in its clinical pipeline and substantial capital raises.

Bank of the James Financial Group reports significant increases in net income, total assets, and net interest margin for fiscal year 2025, driven by strategic growth and cost management.

Vine Hill Capital Investment Corp. announces a definitive business combination agreement with CoinShares International Limited, valuing CoinShares at $1.2 billion, subject to shareholder and regulatory approvals.

Healthier Choices Management Corp. reports recurring net losses and a going concern warning, despite debt restructuring and a new credit facility, following its grocery business spin-off.

Verde Clean Fuels, Inc. has suspended its Permian Basin Project and adopted a capital-lite strategy, focusing on technology licensing amid continued net losses and management changes.

Humacyte, Inc. commenced U.S. commercial sales of its FDA-approved Symvess for vascular trauma in Q1 2025, generating $1.4 million in revenue, but faces substantial doubt about its ability to continue as a going concern.

Muzero Acquisition Corp. details its blank check company structure, successful IPO, and ongoing search for a technology-enabled business combination, with a particular interest in the AI sector.

Empery Digital Inc. has pivoted to a digital asset treasury strategy, divesting its four-wheel vehicle business, but reported a substantial net loss of $150.1 million in 2025, largely due to unrealized Bitcoin losses.

Fennec Pharmaceuticals announced record net product sales of $44.6 million for fiscal year 2025, a 50% increase year-over-year, alongside the full redemption of its outstanding debt.

Dillard's, Inc. reported net income of $570.2 million for fiscal year 2025, maintaining gross margins and returning significant cash to shareholders despite flat retail sales.

Northpointe Bancshares, Inc. announced a significant increase in net income and asset growth for 2025, driven by strategic repositioning and expansion in its Mortgage Purchase Program and All-in-One loan segments.

GSR IV Acquisition Corp., a blank check company, reported a net income of $2.32 million for the year ended December 31, 2025, primarily from trust account interest, as it continues its search for a business combination.

Lifeloc Technologies, Inc. reported a significantly increased net loss for fiscal year 2025, driven by strategic investments in its SpinDetect platform and higher interest expenses, despite a modest revenue increase.

Avidia Bancorp recorded a net loss of $3.3 million in 2025, primarily driven by a significant $19.2 million land loan charge-off, despite an 18.1% increase in net interest income and a substantial capital boost from its initial public offering.

Silo Pharma, a developmental-stage biopharmaceutical and cryptocurrency company, reported a net loss of $4.2 million for 2025 while advancing its drug pipeline and managing a volatile digital asset treasury.

KBS Real Estate Investment Trust III, Inc. reports substantial doubt about its ability to continue as a going concern, with a significant drop in estimated share value and looming debt maturities.

Autolus Therapeutics reports its first commercial sales of AUCATZYL in the US, expands its CAR T-cell therapy pipeline for oncology and autoimmune diseases, and continues to incur significant losses.

Sphere 3D Corp. reports a significant decrease in Bitcoin mining revenue and a net loss for 2025, alongside strategic moves including a merger agreement with Cathedra Bitcoin and a reverse stock split, while facing substantial doubt about its ability to continue as a going concern.

Forian Inc. announced a significant increase in revenue and improved net loss for the fiscal year ended December 31, 2025, driven by organic growth and strategic acquisitions.

Praetorian Acquisition Corp. files its annual 10-K, detailing its blank check status, successful IPO, and ongoing search for a business combination target in traditional sectors transformable by AI and automation.

Talon Capital Corp., a SPAC focused on energy and power, reported a net income of $2.63 million for the period ending December 31, 2025, and outlined its capital structure and business combination strategy.

Jaguar Uranium Corp. outlines its exploration-stage progress in Colombia and Argentina, leveraging recent IPO proceeds to fund operations for the next two years despite a history of losses.

Soren Acquisition Corp., a blank check company, filed its annual report detailing its IPO, search for a business combination in healthcare, and associated financial and operational risks.

VanEck Bitcoin ETF reports significant asset growth in 2025 despite bitcoin price volatility, with a fee waiver for assets under $2.5 billion.

F&M Bank Corp. announced a significant increase in net income for 2025, driven by robust net interest income growth and improved asset quality, despite rising noninterest expenses.

ON24, Inc. filed an amendment to its 2025 annual report to include detailed information on its board of directors, executive compensation, and corporate governance, ahead of its definitive proxy statement.